Zentalis Pharmaceuticals, Inc. (ZNTL)
3.99
-0.12
(-2.92%)
USD |
NASDAQ |
Sep 04, 16:00
3.995
0.00 (0.00%)
Pre-Market: 20:00
Zentalis Pharmaceuticals SG&A Expense (TTM) : 37.06M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 37.06M |
| March 31, 2026 | 36.28M |
| December 31, 2025 | 37.72M |
| September 30, 2025 | 69.82M |
| June 30, 2025 | 73.64M |
| March 31, 2025 | 81.96M |
| December 31, 2024 | 87.12M |
| September 30, 2024 | 63.48M |
| June 30, 2024 | 64.82M |
| March 31, 2024 | 63.72M |
| December 31, 2023 | 64.35M |
| September 30, 2023 | 59.12M |
| June 30, 2023 | 55.18M |
| March 31, 2023 | 59.16M |
| December 31, 2022 | 54.55M |
| Date | Value |
|---|---|
| September 30, 2022 | 53.17M |
| June 30, 2022 | 50.03M |
| March 31, 2022 | 40.76M |
| December 31, 2021 | 40.94M |
| September 30, 2021 | 41.91M |
| June 30, 2021 | 43.14M |
| March 31, 2021 | 42.70M |
| December 31, 2020 | 33.89M |
| September 30, 2020 | 26.20M |
| June 30, 2020 | 17.94M |
| March 31, 2020 | 9.967M |
| December 31, 2019 | 8.459M |
| September 30, 2019 | 5.423M |
| June 30, 2019 | 3.579M |
| March 31, 2019 | 1.633M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| ARS Pharmaceuticals, Inc. | 284.49M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |
| Savara, Inc. | 56.71M |